eFFECTOR Therapeutics, Inc. (EFTR)

eFFECTOR Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	14.88	8.71	49.7	15.22	3.43
Short-Term Investments	3.5	17.6	0	0	0
Cash & Cash Equivalents	18.37	26.31	49.7	15.22	3.43
Cash Growth	-30.18%	-47.06%	226.64%	344.00%	-
Other Current Assets	1.47	1.7	3.19	1.36	0.85
Total Current Assets	19.84	28.01	52.9	16.58	4.27
Property, Plant & Equipment	0.19	0.35	0.26	0.13	0.82
Other Long-Term Assets	0.51	0.71	0.9	0	0
Total Long-Term Assets	0.71	1.06	1.16	0.13	0.82
Total Assets	20.54	29.08	54.06	16.7	5.1
Accounts Payable	2.33	1.49	0.52	0.35	0.6
Current Debt	20.55	20.22	0.04	6.02	15.25
Other Current Liabilities	2.92	3.37	3.42	2.42	3.09
Total Current Liabilities	25.8	25.08	3.98	8.78	18.93
Long-Term Debt	0	0.06	19.99	6.95	0
Other Long-Term Liabilities	0.54	0.05	12.81	0	0
Total Long-Term Liabilities	0.54	0.11	32.79	6.95	0
Total Liabilities	26.34	25.18	36.77	15.73	18.93
Total Debt	20.55	20.28	20.03	12.96	15.25
Debt Growth	1.30%	1.25%	54.54%	-14.98%	-
Retained Earnings	-179.38	-143.57	-120.9	-136.7	-150.91
Comprehensive Income	0	-0.02	0	0	0
Shareholders' Equity	-5.8	3.9	17.28	-132.25	-147.06
Net Cash / Debt	-2.18	6.03	29.67	2.26	-11.82
Net Cash / Debt Growth	-	-79.68%	1215.83%	-	-
Net Cash Per Share	-0.99	3.66	20.60	21.23	-23.86
Working Capital	-5.96	2.94	48.92	7.8	-14.66
Book Value Per Share	-2.65	2.37	28.61	-2343.86	-296.89

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).